Iovance up 13% on completing Biologics License Application submission for lifileucel

Mar. 24, 2023 6:22 PM ETIovance Biotherapeutics, Inc. (IOVA)By: Jonathan Block, SA News Editor1 Comment

Melanoma - a malignant tumor of the skin

Nasekom

  • Iovance Biotherapeutics (NASDAQ:IOVA) is up 13% in after-hours trading Friday after reporting it has completed its rolling Biologics License Application for lifileucel for melanoma.
  • Lifileucel, a tumor infiltrating lymphocyte therapy, is under investigation for patients with advanced melanoma that have failed on anti-PD-1/L1 therapy and targeted therapy.
  • There are no approved treatments for melanoma in this setting.
  • Read why Seeking Alpha contributor BioSci Capital Partners reiterated a strong buy rating for Iovance (IOVA) in February.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.